arrow_back Trending Legislation
Share share

Lower Drug Prices: Studying Intermediaries and Competition in Pharma Market

This act aims to investigate how companies that act as intermediaries in drug delivery, such as pharmacy benefit managers, operate. The goal is to determine if their actions are increasing drug prices or limiting competition. The study's findings will help create new rules to ensure lower drug prices and greater transparency for patients.
Key points
The government will investigate if drug intermediaries (e.g., PBMs) are overcharging for prescription drugs.
It will be examined whether these companies steer patients to their own pharmacies or misuse pharmacy data for their benefit.
The goal is to increase transparency and competition in the drug market, aiming for lower prices for citizens.
New regulations will be proposed to prevent unfair practices and ensure that savings from company mergers benefit consumers.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Prescription Pricing for the People Act of 2021
Print number: S 1388
Sponsor: Sen. Grassley, Chuck [R-IA]
Process start date: 2021-04-27